Lundbeckfonden Ventures is an evergreen venture fund that was founded in 2009 and is entirely owned by the Lundbeck Foundation. It invests in life science companies and focuses on projects and companies close to or in clinical development.
Lundbeckfonden Ventures is a venture fund generating returns to support the group's activities and operating independently from the Lundbeck Foundation controlling ownerships in H. Lundbeck A/S, ALK-Abelló and Falck.
The Lundbeck Foundation
The Lundbeck Foundation is a Danish foundation that was founded in 1954 by Grete Lundbeck and is worth over DKK 60 billion. They award research grants of around DKK 500 million each year to Danish-based, biomedical sciences research, primarily in the field of brain research.
Lundbeckfonden invests in biotechnology and medical companies worldwide with annual investments of 350 to 400 million Danish kroner.The company invests at early and late venture stage.
Amplyx Pharmaceuticals, Inc. is a preclinical stage company focusing on the development of small molecule drugs.
Trevi Therapeutics is a New Haven, Connecticut-based company.
Imara is a Cambridge, Massachusetts-based company.
Anna Jo Dinesen
Head of Talent & Career Programmes
Chief Financial Officer
PA to the CEO
SVP, Director of Science
Head of Strategy
Gitte Grove Stig
Senior Communications Advisor
Håkon Hemme Bro-Jørgensen
Jens Karkov Nørgaard
Documentaries, videos and podcasts
Dysis Medical Ltd.
Psioxus Therapeutics Ltd.
River Vision LLC.
- Venture capitalA form of financing or funding for emerging companies. Investment on early-stage companies in exchange for equity in the companies they invest in.
- The Lundbeck FoundationThe Lundbeck Foundation is one of Denmark’s largest industrial foundations with annual grants for biomedical research of more than DKK 500 million.